JPRN-jRCTs062220027
Recruiting
Phase 1
Randomized multicenter trial for investigating effect of neurofeedback with gait imagery training on Parkinson's disease patients
Mihara Masahito0 sites50 target enrollmentJune 8, 2022
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Mihara Masahito
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) patients who had written informed consent
- •2\) age older than 39 year old
- •3\) PD patients with diagnosis of clinically probable or clinically established PD in MDS criteria
- •4\) Patients with Hoehn\-Yahr stage 2 to 4
- •5\) Patients who can walk 10 m safely with or without aid
- •6\) Patients whose anti\-Parkinsonian drug is not changed for at least 2 months at the time of registration
- •7\) Patients who can understand the verbal order and perform task
Exclusion Criteria
- •1\) moderate to severe dmentia with MMSE score\< 22
- •2\) Patients with cortical lesion covering media premotor area including the supplementary motor area
- •3\) Patients with history of symptomatic stroke or Epilepsy
- •4\) patients with severe Anterior Cerebral Artery stenosis (\>90%)
- •5\) Patients wiht history of neurosurgical operation including Deep brain stimulation and trans\-arterialaneurysm coil embolization)
- •6\) Patients unstable in vital signs
- •7\) Patients with corrected binocular visual acuity less than 1/20
- •8\) Patients with scalp lesion which needed treatment
- •9\) Women with Pregnancy, lactating, or suspected pregnancy
- •10\) Patients who is unable to perform brain MRI scannning
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Trial to evaluate the efficacy of fentanyl pectin nasal spray (FPNS) versus Physician Choice (PC) - Usual Care (UC), in patients with head and neck cancer undergoing radiotherapy.Patients with head and neck cancer .MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-005110-30-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI158
Active, not recruiting
Phase 1
A multicenter randomized trial to evaluate the efficacy of tocilizumab in patients with severe Coronavirus Disease 2019 (Covid-19) pneumonia failing glucocorticoids.polmonite severa da coronavirus 2019MedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-005291-35-ITAOU POLICLINICO DI MODENA640
Recruiting
Phase 1
A multicenter randomized trial to evaluate the efficacy of pioglitazone to improve renal outcome in ANCA-associated vasculitis - RENATOANCA-associated vasculitisTherapeutic area: Diseases [C] - Immune System Diseases [C20]CTIS2022-501057-36-00Assistance Publique Hopitaux De Paris126
Not yet recruiting
Not Applicable
Multicentric, randomized trial to evaluate the efficacy of baseline Immune-risk stratification based on selective Biomarkers (HLA Eplet mismatching and donor-specific IFN-γ ELISPOT) to optimize Immunosuppressive therapy in Living-kidney transplant patientsNL-OMON49228Academisch Medisch Centrum50
Recruiting
Not Applicable
The prophylactic hypothermia trial to lessen traumatic brain injury – randomised controlled trial.Severe traumatic brain injuryNeurological - Other neurological disordersInjuries and Accidents - Other injuries and accidentsACTRN12609000764235Australian and New Zealand Intensive Care-Research Centre, Monash University500